China 
Africa 
Explore chapters and articles related to this topic
Nanomedicines for the Treatment of Gastric and Colonic Diseases
Published in Sarwar Beg, Mahfoozur Rahman, Md. Abul Barkat, Farhan J. Ahmad, Nanomedicine for the Treatment of Disease, 2019
Md. Adil Shaharyar, Mahfoozur Rahman, Kainat Alam, Sarwar Beg, Kumar Anand, Chowdhury Mobaswar Hossain, Arijit Guha, Muhammad Afzal, Imran Kazmi, Rehan Abdur Rub, Sanmoy Karmakar
Chronic pancreatitis is an inflammation (Kumar et al., 2005) of the pancreas which gets worse with the passage of time, permanently damaging the pancreas. The reason behind damaging of the pancreas is same as that of acute pancreatitis. Alcohol is the main rogue behind chronic pancreatitis as it slowly damages the pancreatic duct. Other reasons involved are hereditary disorders related to pancreas, cystic fibrosis, hypercalcemia, hyperlipidemia, autoimmune disease, unknown causes and some medicines (Kumar et al., 2005). In most of the patient, there is an emergence of upper abdominal pain which may affect the back and the pain worsens with eating and drinking (Warshaw et al., 1998). The pathway of the pain is the same as that of acute pancreatitis. The pain subsides with the progression of the disease as enzymes secretion stops. Oily stool, weight loss, and nausea are other symptoms associated with chronic pancreatitis (Warshaw et al., 1998).
Ensemble based biomarker identification on pancreatic ductal adenocarcinoma gene expressions
Published in International Journal of Computers and Applications, 2021
Purbanka Pahari, Piyali Basak, Anasua Sarkar
Pancreatic ductal adenocarcinoma is the most widely recognized type of pancreatic malignancy, making up more than 80% of cases [1]. It is an epithelial tumor starts in the cells of the pancreas’ channels, which transport juices containing critical stomach related proteins into the little intestine [2]. The nearly happening side effects of PDAC are weight reduction, agony and basic clinical sign is jaundice. There are some more restorative Conditions, for example, Chronic pancreatitis, intense pancreatitis, diabetes, cirrhosis, Helicobacter pylori disease, human immunodeficiency infection (HIV) contamination, hepatitis B, cystic fibrosis, stoutness. Genetic disorder as example – Family history of pancreatic malignancy, Lynch disorder, Li-Fraumeni disorder numerous endocrine neoplasia 1, innate bosom and ovarian tumor, Familial atypical various mole melanoma disorder, von-Hippel Lindau disorder, Peutz-Jegher disorder and way of life like – tobacco utilize, substantial; liquor utilize, high fat or cholesterol eat less which causes PDAC.
α-Amylase assay with starch–iodine–sodium fluorescein-based fluorometric method in human serum samples
Published in Preparative Biochemistry & Biotechnology, 2021
Julide Buse Zafer, Süreyya Dede, Emine Karakuş
We have developed a novel fluorometric method for the determination of α-amylase activity in human serum samples. The SIF-based fluorometric method was based on the measurement of increased fluorescence emission intensity after decomposition of our prepared SIF complex by α-amylase enzymatic hydrolysis. The optimum pH, buffer concentration, and temperature for the SIF-based fluorometric method were found to be 8.5, 0.1 M, and 25 °C, respectively. Glucose, urea, and creatinine, which commonly found in the blood, weren’t detected interference effects on our method. The method is simple, sensitive, and rapid, and allows the measurement of α-amylase activity at levels as low as 0.18 U/L. The detection of low amounts of α-amylase may be advantageous in the diagnosis of diseases such as kidney malfunction, toxemia of pregnancy, chronic pancreatitis, type 1 diabetes, and cystic fibrosis. α-Amylase is typically found at 25–85 U/L in the blood serum of healthy individuals but the levels are reduced in patients with the abovementioned conditions.[53,57] We found a good correlation between the results obtained with the proposed SIF-based fluorometric method and the results obtained in the medical center for α-amylase in serum samples.
The effectiveness of Hemopatch™ in preventing postoperative distal pancreatectomy fistulas
Published in Expert Review of Medical Devices, 2019
Anna Pisapia, Enrico Crolla, Michele Saracco, Alessandro Saglioccolo, Pasquale Dolce, Carlo Molino
Distal pancreatectomy (DP) is the standard surgical procedure for treating chronic pancreatitis and benign and malignant lesions located in the body or tail of the pancreas. Although both short- and long-term survival rates have markedly improved, postoperative morbidity and mortality associated with pancreatic fistulas remain considerable after DP [1]. To date, surgeons lack an effective tool for preventing this complication. Hemopatch™ is a sealing hemostatic device that consists of a soft, thin, pliable, flexible pad of collagen derived from the bovine dermis and coated with pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate. Hemopatch™ is indicated for procedures in which control of bleeding or leakage of other body fluids or air by conventional surgical techniques is either ineffective or impractical [2]. Hemopatch™ is structurally different from other sealants; thanks to its coating in NHS-PEG, Hemopatch™ achieves hemostasis by a dual-method mechanism: sealing off the bleeding surface and initiating body’s own clotting mechanism.